IL33 and colitis: Moreover, GLP-1RA treatment modulates the expression of additional barrier-associated genes, including IL-33, mucins, and CCL20—although the direction and magnitude of regulation vary depending on the colitis model, disease timepoint, and genetic background, complicating interpretation.9